These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33667955)

  • 1. Influence of PAR-1 in patients with non-valvular atrial fibrillation: The antiplatelet effect of dabigatran.
    Oi K; Shimizu M; Natori T; Tsuda K; Yoshida M; Kamada A; Ishigaku Y; Narumi S; Oura K; Maeda T; Terayama Y
    Thromb Res; 2021 May; 201():123-130. PubMed ID: 33667955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel antithrombotic effects of dabigatran in patients with non-valvular atrial fibrillation.
    Tsuda K; Natori T; Shimizu M; Ishigaku Y; Oi K; Narumi S; Kamada A; Yoshida M; Oura K; Maeda T; Terayama Y
    Thromb Res; 2020 May; 189():1-4. PubMed ID: 32120029
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of dabigatran on platelet function and fibrinolysis.
    Tsantes AE; Kyriakou E; Bonovas S; Chondrogianni M; Zompola C; Liantinioti C; Simitsi A; Katsanos AH; Atta M; Ikonomidis I; Kapsimali V; Kopterides P; Tsivgoulis G
    J Neurol Sci; 2015 Oct; 357(1-2):204-8. PubMed ID: 26219486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anticoagulant effect of therapeutic levels of dabigatran in atrial fibrillation evaluated by thrombelastography (TEG
    Solbeck S; Jensen AS; Maschmann C; Stensballe J; Ostrowski SR; Johansson PI
    Scand J Clin Lab Invest; 2018; 78(1-2):25-30. PubMed ID: 29304563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
    Semeraro F; Incampo F; Ammollo CT; Dellanoce C; Paoletti O; Testa S; Colucci M
    Thromb Res; 2016 Feb; 138():22-29. PubMed ID: 26826504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombin induces protease-activated receptor 1 signaling and activation of human atrial fibroblasts and dabigatran prevents these effects.
    Altieri P; Bertolotto M; Fabbi P; Sportelli E; Balbi M; Santini F; Brunelli C; Canepa M; Montecucco F; Ameri P
    Int J Cardiol; 2018 Nov; 271():219-227. PubMed ID: 29801760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expectation to and problems of thrombin inhibitor].
    Uchiyama S
    Rinsho Shinkeigaku; 2011 Nov; 51(11):1004-6. PubMed ID: 22277458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation.
    Achilles A; Mohring A; Dannenberg L; Grandoch M; Hohlfeld T; Fischer JW; Levkau B; Kelm M; Zeus T; Polzin A
    J Thromb Haemost; 2017 Mar; 15(3):473-476. PubMed ID: 27992120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of thrombin-bound dabigatran effects on protease-activated receptor-1 expression and signaling in vitro.
    Chen B; Soto AG; Coronel LJ; Goss A; van Ryn J; Trejo J
    Mol Pharmacol; 2015 Jul; 88(1):95-105. PubMed ID: 25934730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Direct Thrombin Inhibitors Dabigatran and Lepirudin Inhibit GPIbα-Mediated Platelet Aggregation.
    Trabold K; Makhoul S; Gambaryan S; van Ryn J; Walter U; Jurk K
    Thromb Haemost; 2019 Jun; 119(6):916-929. PubMed ID: 31005062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient perception and treatment convenience of dabigatran versus vitamin K antagonist when used for stroke prophylaxis in atrial fibrillation: Real-world Evaluation of Long-term Anticoagulant Treatment Experience (RE-LATE) study.
    Lee YS; Oh YS; Choi EK; Chern AKC; Jiampo P; Chutinet A; Hanafy DA; Trivedi P; Zhai D
    Open Heart; 2021 Dec; 8(2):. PubMed ID: 34857666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Dabigatran on Clotting Time in the Clotpro Ecarin Clotting Assay: A Prospective, Single-Arm, Open-Label Study.
    Fong AYY; Tiong LL; Tan SSN; Geruka D; Apil GG; Choo CW; Ong TK
    Clin Appl Thromb Hemost; 2020; 26():1076029620972473. PubMed ID: 33284050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Idarucizumab to reverse the anticoagulant effect of dabigatran in cardiac transplant surgery. A multicentric experience in Spain.
    Crespo-Leiro MG; López-Vilella R; López Granados A; Mirabet-Pérez S; Díez-López C; Barge-Caballero E; Segovia-Cubero J; González-Vilchez F; Rangel-Sousa D; Blasco-Peiró T; de la Fuente-Galán L; Díaz-Molina B; Zatarain-Nicolás E; Carrasco Ávalos F; Almenar-Bonet L
    Clin Transplant; 2019 Dec; 33(12):e13748. PubMed ID: 31670852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran.
    Olivier CB; Weik P; Meyer M; Weber S; Anto-Michel N; Diehl P; Zhou Q; Geisen U; Bode C; Moser M
    Thromb Res; 2016 Feb; 138():63-68. PubMed ID: 26610745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis.
    Koretsune Y; Yamashita T; Yasaka M; Ono Y; Hirakawa T; Ishida K; Kuroki D; Sumida T; Urushihara H
    J Cardiol; 2019 Mar; 73(3):204-209. PubMed ID: 30477926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
    Amin A; Keshishian A; Dina O; Dhamane A; Nadkarni A; Carda E; Russ C; Rosenblatt L; Mardekian J; Yuce H; Baker CL
    J Thromb Thrombolysis; 2019 Aug; 48(2):240-249. PubMed ID: 30924051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
    Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
    Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation.
    Oertel LB; Fogerty AE
    J Am Assoc Nurse Pract; 2017 Sep; 29(9):551-561. PubMed ID: 28805310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between activated partial thromboplastin time, age and bleeding events in NVAF patients receiving dabigatran.
    Ji Q; Xu Q; Wang Z; Li X; Lv Q
    Eur J Clin Pharmacol; 2019 Mar; 75(3):321-328. PubMed ID: 30377709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.